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Abstract
Background: Ceftriaxone is one of the most commonly used antibiotics due to its high antibacterial potency, wide
spectrum of activity and low potential for toxicity. However, the global trend shows misuse of this drug. The aim of
this study was to evaluate prospectively the appropriateness of ceftriaxone use in medical and emergency wards of
Tikur Anbessa Specialized Hospital.
Methods: A prospective cross-sectional study was conducted by reviewing medication records of patients
receiving ceftriaxone during hospitalization at Tikur Anbessa Specialized Hospital between February 1 and June 30,
2014. Drug use evaluation was conducted to determine whether ceftriaxone was being used appropriately based
on six criteria namely indication for use, dose, frequency of administration, duration of treatment, drug-drug
interaction, culture and sensitivity test. The evaluation was made as per the protocol developed from current
treatment guidelines.
Results: The total of 314 records of patients receiving ceftriaxone was reviewed. The prescribing rate of ceftriaxone
was found to be very high (58 % point prevalence). Ceftriaxone use was empiric in 274 (87.3 %) cases. The most
common indication for ceftriaxone use was pneumonia; observed in 110 (35.0 %) cases. The most common daily
dosage, frequency of administration and duration of treatment with ceftriaxone were 2 g (88.9 %), twice-daily
(98.4 %) and 8-14 days (46.2 %), respectively. Inappropriate use of ceftriaxone was observed in most of cases
(87.9 %), the greatest proportion of which was attributed to inappropriate frequency of administration (80.3 %),
followed by absence of culture and sensitivity test (53.2 %).
Conclusion: This study revealed that the inappropriate use of ceftriaxone was very high in the medical and
emergency wards of Tikur Anbessa Specialized Hospital. This may lead to emergence of resistant pathogens which
in turn lead to treatment failure and increased cost of therapy. Therefore, adherence to current evidence-based
guidelines is recommended.
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Background
Ceftriaxone is a broad-spectrum third generation ceph-
alosporin antibiotic for intravenous or intramuscular ad-
ministration. It is one of the most commonly used
antibiotics due to its high antibacterial potency, wide
spectrum of activity and low potential for toxicity [1].
The most likely reason for its widespread use is its ef-
fectiveness in susceptible organisms in complicated and
uncomplicated urinary tract infections, respiratory tract
infections, skin, soft tissue, bone and joint infections,
bacteremia/septicemia [2], meningitis [3], infections in
immunosuppressed patients, acute bacterial otitis media
[4], genital infections, disseminated Lyme’s disease and
in surgical prophylaxis of infections [5]. It is worthy to
note that antimicrobials are among the most commonly
used and misused of all drugs [6, 7].
Despite strenuous efforts to control their use and pro-
mote optimal prescribing, practitioners still continue to
prescribe excessively [8, 9]. But, the inevitable conse-
quence of the widespread use of antimicrobials and ex-
tended duration of use, use of suboptimal doses and
longer stay in hospitals are additional risk factors that
have contributed to the emergence and dissemination of
antimicrobial resistance [10]. Antibiotic resistance is a
major factor contributing to increased morbidity and
mortality of patients as well as cost of medical care. For
instance, it is cited in the work of Lee et al. [1] that anti-
microbial drug resistance has been projected to add be-
tween $100 million and $30 billion annually to health-
care costs. In line with this, it was reported that the in-
appropriate use of ceftriaxone caused, worldwide, an an-
nual cost of $4-5$ million pertaining to infection caused
by antibiotic resistant bacteria [11]. The other study con-
ducted in Spain regarding the use of third generation
cephalosporins, wherein ceftriaxone was the most fre-
quently prescribed agent, found out that the cost of in-
appropriate antibiotic use was twice as much for
patients who were treated appropriately [12].
The problem of antibiotic resistance has noticeably
worsened in Ethiopia during the past several years. As-
sessment conducted by Food, Medicine and Healthcare
Administration and Control Authority of Ethiopia has
shown that it is not only higher utilization but also ir-
rational use of antibiotics has been increased. This in
turn is also associated with fueling an ever-increasing
need for new drugs. Therefore, prudent prescribing of
antimicrobial drugs is essential as it may reduce inci-
dences of antimicrobial drug resistance [13, 14].
In Ethiopia, there is no any prospective study that evalu-
ated ceftriaxone utilization. In addition, the retrospective
studies conducted regarding this issue were only few. For
example, there was retrospective study conducted to com-
paratively evaluate the use of ceftriaxone in Police Referral
Hospital and Tikur Anbessa Specialized Hospital but it
involved small sample size [9]. On the other hand, other
local retrospective studies done regarding ceftriaxone
utilization did not consider duration of treatment and cul-
ture and sensitivity test as criteria. Therefore, the present
study overcame limitations of the previous studies by
using improved study design (prospective cross-sectional
study). Furthermore, all wards of the internal medicine
and emergency departments were included to enhance the
generalizability of the study findings. Thus, the present
study is designed to evaluate the appropriateness of ceftri-
axone utilization and to assess reasons for its inappropri-




This study was institution based research conducted in
the medical and emergency wards of Tikur Anbessa Spe-
cialized Hospital which is located in Addis Ababa,
Ethiopia. Tikur Anbessa Specialized Hospital is an 800
bed tertiary care teaching hospital of Addis Ababa Uni-
versity. This hospital offers diagnosis and treatment for
approximately 370,000 - 400,000 patients a year.
Study design
A prospective cross-sectional study was conducted to
carry out drug use evaluation by reviewing medical re-
cords of patients who received ceftriaxone between Feb-
ruary 1 and June 30, 2014. The drug use evaluation was
made as per the criteria of the currently developed
protocol regarding the rational use of this drug. The
treatment protocol was prepared by the joint effort of
professionals from School of Pharmacy and School of
Medicine. It was prepared by compiling current
evidence-based recommendations regarding the use of
this drug from WHO guideline 2013, STG of Ethiopia
2010, and other sources of information such as Harri-
son’s Principles of Internal Medicine 2012, The Sanford
Guide to Antimicrobial Therapy 2012, UpToDate, Meds-
cape, and other peer-reviewed journals. More focus was
given to “The Sanford Guide to Antimicrobial Therapy”
as this guide is among the most widely accepted guide-
lines in many parts of the world.
Source and study population
All patients admitted to medical and emergency wards
of Tikur Anbessa Specialized Hospital constituted the
source population. All in-patients in the medical and
emergency wards of Tikur Anbessa Specialized Hospital
admitted between February 1 and June 30, 2014 were
taken as the study population. All eligible patients in-
cluded in the study were followed until they complete
their treatment with ceftriaxone. To manage patients
who transferred from their initial department of
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admission to another, the mobile number of the patients
or their attendants was registered for each patient in-
cluded in the study (especially for those admitted to the
emergency department). Most of them were transferred
from the emergency department to internal medicine
department, and some were transferred to the ortho-
pedic department.
Sample size determination
Sample size was calculated using the single proportion
formula at 95 % confidence interval and p value of 0.5.
The sample size was adjusted based on the total number
of patients who were estimated to take ceftriaxone dur-
ing the study period (N = 923), the required minimum
sample with addition of 10 % contingency was finally
299. But, a relatively larger number of participants (314
patients) were included in the present study to maximize
its generalizability.
Inclusion and exclusion criteria
In-patients whose age ≥18 years were eligible provided
that they took ceftriaxone during the study period at
each of the selected wards. On the other hand, patients
who refused to participate in the study and patients
with medical records of insufficient or illegible informa-
tion were excluded. Outpatients were also excluded from
the study as it is not convenient to make a follow up
study (eg. for any possibility of bleeding and other
phenomena).
Data collection
Data were collected by trained pharmacists via reviewing
medication charts of patients admitted during the study
period by using patient data collection format. The con-
tent of the data collection format was designed to record
patient information, disease condition, admission and
discharge dates, working diagnosis, past medical history,
physical examination, sign and symptoms, abnormal la-
boratory tests, abnormal diagnostic results, C&S results,
information regarding administration of ceftriaxone in-
cluding its indication, dose, frequency of administration,
duration of therapy, and information regarding co-
administered medications.
Key informant interview
Data was collected by self-administered questionnaire to
physicians (n = 10) practicing in the infectious disease
unit and microbiologists (n = 6) from microbiology la-
boratory of Tikur Anbessa Specialized Hospital. They
were selected based on their long time professional ex-
perience in the study area. Accordingly, consultant phy-
sicians, senior residents and microbiologists were
selected.
Data quality control
The data collection format was pretested. Additionally,
data collectors were trained on how to use such formats
and how to approach other health care workers. Further-
more, the data collection process was checked continu-
ously by the principal investigator on daily basis for its
completeness and accuracy before the patient gets
discharged.
Data analysis
Drug use evaluation was conducted to determine
whether ceftriaxone was being used appropriately based
on the protocol currently prepared regarding the ration-
ale use of ceftriaxone. Six criteria namely indication for
use, dose, frequency of administration, duration of treat-
ment, drug-drug interaction, culture & sensitivity test
were used to evaluate its use.
The data outcomes from those evaluations were en-
tered and analyzed by SPSS version-16.0. In computing
the overall appropriateness of ceftriaxone utilization, its
use with respect to each of the six criteria was deter-
mined for each patient as per the protocol.
The appropriate use of ceftriaxone was computed by
dividing the number of cases considered appropriate
with respect to all the six criteria to the total number of
cases. But, in computing the appropriateness of a given
criteria, the number of cases with appropriate dosing
was divided by the total number of cases. The responses
of key informants were analyzed using content thematic
analysis. Accordingly, the collected key informant’s re-
sponse was first made well familiarized and then signifi-
cant themes (patterns) were identified. Finally, analysis
of the themes were made and contextualized in relation
to the existing literature. Binary logistic regression and
multivariate logistic regression analysis was made to ob-
serve whether there was association between independ-
ent variables versus inappropriate ceftriaxone use.




A total of 314 patients were included in this study of
which 53.8 % were males. Most of the study participants
were adults in the age group of 18-65 (90.8 %) with
mean age of 37.7 ± 17.2. The socio-demographic charac-
teristics of participants were summarized below
(Table 1).
Ceftriaxone prescription pattern
The utilization rate of ceftriaxone was found to be very
high (58 % point prevalence) at the medical and emer-
gency wards of Tikur Anbessa Specialized Hospital dur-
ing the study period. It was found out that 55.1 % of
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cases received ceftriaxone for diseases where it is indi-
cated as first-line therapy according to current evidence-
based guidelines. However, it was prescribed empirically
for most of the cases (87.3 %). The top indications for
ceftriaxone use were respiratory tract infections (35.4 %),
prophylactic indications (11.1 %), and skin, soft tissue
and bone infections (10.8 %) (Table 2).
Dosing and duration of ceftriaxone use
The most commonly prescribed dose of ceftriaxone was
1 g (87.9 %) and most used frequency of administration
being twice-daily dosing (98.4 %). The mean duration of
treatment was found to be 10.4 days (range: 1-56 days).
In most cases, it was used for 8-14 days (46.2 %)
(Table 3).
Culture and sensitivity test
Culture and sensitivity test was not done in most of the
patients (89.5 %). In more than half of the patient
(53.2 %) this test was not sent for unacceptable reason.
Some of the accepted reasons why the test was not sent
for investigation were prior initiation of therapeutic anti-
biotic regimen (25.8 %) and the use of ceftriaxone for its
prophylactic indications (10.5 %). Of the 33 cases in
which test was done, growth was observed in 8 cases
(24.2 %). The organisms were found to be resistant in
nearly two third of cases (62.5 %) of cultures on which
growth was observed.
Concomitant administration of drugs
As shown in Fig. 1, the most concomitantly adminis-
tered drugs with ceftriaxone were metronidazole
(37.9 %), tramadol (33.8 %), azithromycin (25.5 %) and
cimetidine (23.2 %). Inappropriate concomitant use of
ceftriaxone was observed as it was co-administered with
ringer lactate (observed in 6.7 % of cases). This consti-
tuted major drug-drug interaction which may increase
the probability of IV incompatibility between the two
drugs as a result of binding of ceftriaxone to the calcium
contained in ringer lactate. In addition, concomitantly
used drugs with moderate interactions were heparin
(22.6 %) and warfarin (6.7 %). Six patients (1.9 %) with
this type of co-administration experienced either bleed-
ing or increased INR, among which death due to exces-
sive bleeding occurred in one patient.
Table 1 Socio-demographic characteristics of patients included
in the study in medical and emergency wards of Tikur Anbessa
Specialized Hospital, 2014 (n = 314)
Characteristics Category No (%)
Sex Male 169 (53.8)
Female 145 (46.2)
Age 18-65 285 (90.8)
≥65 29 (9.2)
Department Internal medicine 231 (73.6)
Emergency 83 (26.4)
Unit of admission Non-ICU 294 (93.6)
ICU 20 (6.4)
ICU intensive care unit
Table 2 The prescription pattern of ceftriaxone for the study participants in medical and emergency wards of Tikur Anbessa
Specialized Hospital, 2014 (n = 314)
Characteristics Category No (%)
Indication of ceftriaxone Primary 173(55.1)
Alternative 83(26.4)
Not indicated 58(18.5)
Type of treatment Therapeutic Empiric 274(87.3)
Specific 5(1.6)
Prophylactic 35(11.1)
Reasons for ceftriaxone use Respiratory tract infection 111(35.4)
Prophylactic indications 35(11.1)
Skin, soft tissue and bone infection 34(10.8)
Central nervous system infection 28(8.9)
Sepsis and septic shock 15(4.8)
Cardiovascular infection 11(3.5)
Urinary tract infection 10(3.2)
Gastro-intestinal infection 6(1.9)
No indication 58(18.5)
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Practice of ceftriaxone utilization versus current protocol
Most of the ceftriaxone prescriptions (87.9 %) were
found to be inappropriate as per the protocol prepared
regarding its rationale use. The greatest proportion of
inappropriate use was attributed to inappropriate fre-
quency of administration (80.3 %), followed by absence
of culture and sensitivity test (53.2 %) and inappropriate
duration of treatment (50 %). The remaining inappropri-
ate use was attributed to dose (21 %), indication (18.5 %)
and drug-drug interactions (8.7 %) as shown in Fig. 2.
Analysis of the practice also indicated that the propor-
tion of inappropriate use was slightly more in the emer-
gency ward compared to the medical wards (90.4 %
versus 87 %). In terms of the first few top indications,
the analysis of practice indicated that the inappropriate
use of ceftriaxone was by far greater than the appropri-
ate use in pneumonia, trauma/injury and wet gangrene
(Table 4).
Factors associated with inappropriate ceftriaxone use
Analysis using binary logistic regression indicated that
gender, age and department type were not significantly
associated with inappropriate ceftriaxone use. By con-
trast, the type of therapy with ceftriaxone was found
to have a significant association with inappropriate
utilization of this drug (p = 0.002). Accordingly, ceftriax-
one use was significantly inappropriate when used as
empiric than specific therapy. Multivariate logistic re-
gression analysis was performed to control the effect of
any confounder and ensured the presence of such asso-
ciation (Table 5). The responses of key informant inter-
view are summarized in Table 6.
Discussion
This study was designed to evaluate the appropriateness
of ceftriaxone utilization in medical and emergency wards
of Tikur Anbesa Specialized Hospital. The current study
showed a very high utilization rate of ceftriaxone (58 %
point prevalence). This is similar with the results obtained
in General Hospital, Port of Spain, in which most of the
studied patients (66 %) received ceftriaxone [7]. High rate
ceftriaxone prescribing practice was also reported by other
studies. This higher utilization of ceftriaxone has been
Table 3 Dosing and duration of treatment with ceftriaxone in medical and emergency wards of Tikur Anbessa Specialized Hospital,
2014 (n = 314)
Dose (gm) N (%) Daily dose (gm) N (%) Duration (days) Frequency (%)
1 276 (87.9) 1 1 (0.3) 1 9(2.9)
1.5 1 (0.3) 2 279 (88.9) 2-7 117(37.3)
2 37 (11.8) 3 1 (0.3) 8-14 145(46.2)
4 33 (10.5) 15-21 33(10.5)
>21 10(3.2)
Fig. 1 Drugs concomitantly prescribed with ceftriaxone in medical and emergency wards of Tikur Anbessa Specialized Hospital, 2014
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ascribed by the good availability of the drug, good effect-
iveness and low toxicity rates [15–17].
Ceftriaxone was empirically prescribed (87.3 %) for its
therapeutic indication (88.9 %) in our study. This is
higher than the empiric use of antibiotics in the study
conducted at the University hospital of the West Indies,
where two-thirds of patients (67.9 %) were treated with
empiric antibiotics [18]. The difference may be attrib-
uted to the fact that the latter study included other add-
itional antibiotics in determining the rate of empiric
antibiotic use.
In this study, the most common indication for ceftri-
axone use was for pneumonia (35 %) followed by re-
spiratory tract infection (35.4 %). This is similar with the
finding in Dessie Referral Hospital, wherein the most
common indication (36.4 %) of this drug was pneumonia
[11]. But in the study conducted at Ayder Referral Hos-
pital, ceftriaxone was most commonly prescribed for
preoperative prophylaxis followed by pneumonia [19].
This difference may be attributed to the inclusion of
surgery department in the latter study.
It was observed that culture and sensitivity test was
not done for more than half of patients (53.2 %) without
acceptable reason. This is higher than the result ob-
tained from the study conducted in Korea, in which un-
acceptable level of culture and sensitivity tests prior to
the initial ceftriaxone dose accounted for 33.5 % [1]. In
the present study, the interviewed physicians agreed that
culture and sensitivity tests were not done in majority of
cases and this was ascribed by unavailability of service,
unreliable culture result, prior initiation of therapeutic
antibiotic regimen and delayed culture result. The inter-
viewed microbiologists agreed that the reason why the
bacteriology results were unconvincing could be due to
sample collection after initiation of antibiotics, use of ex-
pired reagents or antibiotic discs, inappropriate sample
collection, improper use of transporting medium, and
failure to request appropriate laboratory test. They
agreed that the quality of the current microbiology la-
boratory is poor due to mainly to poor quality reagents
and it takes, on average, 3 days for culture results to be-
come available. This is similar with the finding from the
study conducted at the University hospital of the West
Indies, where culture reports took a mean of 3.7 days to
become available [18].
Microbial growth on culture & sensitivity test was ob-
served only in a quarter of samples sent for investigation
(24.2 %) in present study. This is lower than the values
obtained from studies done at Pakistan (31.4 %), Nepal
(47.4 %) and Bangladesh (77 %) [20–22]. The difference
may be attributed to the variation in sample sizes and
the quality of microbiology laboratory. In the present
study, out of cases for which sensitivity was done, resist-
ance to ceftriaxone was seen in nearly two-third of cases
(62.5 %). This is similar with the finding from study con-
ducted in Khartoum (64 %) [14]. But it is lower than the
finding from study conducted in Bahir Dar (82 %) [23].
This difference could be attributed to differences in the
number of tested microorganisms and the prescribing
practice of the drug.
In the present study, it was found out that the most
common prescribed dose of ceftriaxone was 1 g
(87.9 %), whereas, the most common daily dosage was
Fig. 2 Criteria referenced inappropriate use of ceftriaxone in medical and emergency wards of Tikur Anbessa Specialized Hospital. DDI: drug-drug
interaction, C& S: culture and sensitivity test
Table 4 Appropriateness of ceftriaxone use among the top few
indications in medical and emergency wards of Tikur Anbessa
Specialized Hospital, 2014 (n = 314)
Indication Appropriate use N (%) Inappropriate use N (%)
Pneumonia CAP 0 (0) 75 (100)
AP 0 (0) 30 (100)
HAP 0 (0) 5 (100)
Trauma/Injury 2 (10.5) 17 (89.5)
Pyogenic meningitis (52.9) 8 (47.1)
Sepsis 9 (69.2) 4 (30.8)
Cellulitis 6 (46.2) 7 (53.8)
Wet gangrene 0 (0) 12 (100)
Brain abscess 7 (63.6) 4 (36.4)
CAP community acquired pneumonia, AP aspiration pneumonia, HAP hospital
acquired pneumonia
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2 g (88.9 %). This finding is different from the findings
from the other similar studies, wherein the most com-
mon daily dosage of the drug was 2 g in 63.6 % and
79.4 % cases, respectively [11, 19]. One of the possible
reasons for the difference could be the inclusion of pa-
tients of all age group in the latter studies in which
pediatrics received lower daily doses of ceftriaxone [19].
The other staggering finding in the present study was
regarding the frequency of administration with ceftriax-
one, where the twice-daily administration accounted for
almost all cases (98.4 %). Among the other criteria, fre-
quency of administration took the first place in contrib-
uting to the inappropriate use of ceftriaxone; the
inappropriate use of ceftriaxone with this criterion was
observed in 80.3 % of cases. This is similar with the re-
sult obtained in an interventional study done at USA, in
which a significant number of patients received a twice-
daily dosing of ceftriaxone while they were supposed to
receive a once-daily dosing regimen [24]. The reason for
administration of ceftriaxone on a twice-daily basis ac-
cording to key informant physicians interviewed in the
present study was just because of tradition of practice.
It was also found out in the present study that the
mean duration of treatment with ceftriaxone (10.39 days,
range: 1 to 56) is very similar with the findings from the
studies conducted at 10 University hospitals of Korea
where it was found to be 10.3 days (range, 1 to 61) [1].
But, it is different from the values observed in studies
conducted at other hospitals, where it was found to be
7.2 days and 6.8 days, respectively [11, 19]. These differ-
ences could be attributed to the difference in patient
condition; patients who admit to Tikur Anbessa Special-
ized Hospital may be those who are, in most cases,
terminally-ill requiring longer hospital stay and this in
turn may cause physicians to opt long duration of treat-
ment with antibiotics.
The inappropriate duration of treatment with ceftriax-
one took the third place in contributing to the overall
inappropriate utilization of this drug; observed in 50 %
of cases. This was comparable with the finding from the
Korean study (42.8 %) [1]. Treatment with ceftriaxone
was continued without switching to oral medication in
two-third of patients (66.2 %) who deserved switching.
Analysis of the practice also indicated that ceftriaxone
was used for prolonged duration (4-7 days) in its use for
prophylactic purpose as in surgery and trauma. But in
these conditions a one-day prophylaxis with the drug is
the usual recommendation although up to 3 days may
be recommended based on the grade of the wound [25,
26]. The interviewed physicians agreed that such prac-
tices were due to lack of guideline and unavailability of
equivalent oral medications.
Analysis of the practice indicated that metronidazole
took the first place among drugs co-administered with
ceftriaxone (37.9 %). Among drugs with potential for
interaction, concomitant administration with ringer
Table 5 Factors associated with inappropriate ceftriaxone use at Tikur Anbessa Specialized Hospital
Variable Appropriateness COR (95 % CI) AOR (95 % CI) P value
No Yes
Gender
Male 147 22 0.829(0.417:1.646) 0.771(0.358:1.658) 0.505
Female 129 16 1.00 1.00
Age
18-65 250 35 0.824 (0.237:2.866) 0.669(0.164:2.721) 0.574
>65 26 3 1.00 1.00
Department
Emergency 75 8 1.399 (0.614:3.189) 1.557(0.549:4.422 0.405
Internal medicine 201 30 1.00 1.00
Unit
Non-ICU 260 34 1.912 (0.604:6.053) 2.535(0.730:8.804) 0.143
ICU 16 4 1.00 1.00
Treatment type
Empiric 243 31 31.355(3.395:289.55) 36.98(3.884:352.072) 0.002
Specific 1 4 1.00 1.00
Diagnosis
Suspected 146 19 1.123 (0.570:2.213) 1.379(0.648:2.931) 0.404
Confirmed 130 19 1.00 1.00
COR crude odds ratio, AOR adjusted odds ratio, ICU intensive care unit, CI confidence interval
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lactate constituted major drug-drug interaction and was
prescribed in a considerable proportion of cases (6.7 %).
The most common type of potential drug-drug inter-
action identified was due to co-administration with hep-
arin (22.6 %) and warfarin (6.7 %). This type of co-
administration may result in increased risk of bleeding.
In line with this, 6 patients (1.9 %) with this type of co-
administration experienced either bleeding or increased
INR, among which death due to excessive bleeding oc-
curred in one patient. The interviewed physicians agreed
that such practice was due to the less availability of
other drugs and absence of checking for possible inter-
action before prescribing.
The inappropriate use of ceftriaxone was found to be as
high as 87.9 % in or study. This finding is similar with the
result obtained from the study done at Iran, where the
utilization of ceftriaxone was not according to protocol in
85.3 % cases [27]. But, it is higher than the values obtained
from studies conducted at Ayder Referral Hospital and
Dessie Referral Hospital, in which inappropriate use of
Table 6 Responses of the interviewed physicians and microbiologists regarding ceftriaxone use and culture & sensitivity test in
medical and emergency wards of Tikur Anbessa Specialized Hospital, 2014
Interview questions Responses Number of
respondents
Responses of interviewed Physicians
Why was culture & sensitivity not sent for most of the patients? Service is not available 8
Patients come after initiation of antibiotics 5
Culture results are not reliable 5
It takes long time to get results back 2
Why was ceftriaxone administered on a twice-daily basis for most
cases?
Just because of tradition of practice 5
There are guidelines which promote it 4
To ensure its effectiveness 2
Why is the utilization rate of ceftriaxone very high in TASH? Good availability 8
Good effectiveness 5
Low rates of toxicity 4
Ease of administration 4
Why is ceftriaxone being co-administered with ringers lactate, warfarin
and heparin?
Less availability of other drugs 5
No problem up on such administration 4
Absence of checking for interaction 2
Why is ceftriaxone used in neutropenic fever,periodontal abscess, etc? Cost of other more appropriate drugs 4
Unavailability of other appropriate drugs 4
Why was ceftriaxone used for prolonged duration as in surgical
prophylaxis?
Unavailability of equivalent PO medicines 3
Lack of guidelines 2
It should not have been used this way 1
Responses of the interviewed microbiologists
What can you say about the quality of microbiology laboratory? Poor quality due to the use of expired reagents or
antibiotic discs
4
Currently, its quality is improved 2
Why is most culture & sensitivity tests end up with negative result? Sample collection after initiation of antibiotics 4
Use of expired reagents or antibiotic discs 3
Inappropriate sample collection 2
Failure to request appropriate laboratory test 1
Improper use of transporting medium 1
Who will take the bacteriology test result after it is done? Physicians 5
Patients 3
Attendants 1
On average, how long does it take for C&S result to come back (in
day)?
Mostly 3 days 5
Some cultures (eg. blood culture requires 7-14 days) 3
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this drug was observed in 64.2 % and 46.2 % cases, re-
spectively [11, 19]. These differences may be attributed to
the retrospective nature of the studies causing them to
consider less number of criteria in evaluating the use of
the drug. The other major possible reason for the discrep-
ancy may be attributed to the guidelines used in making
the drug use evaluation; the retrospective studies used
Ethiopian standard treatment guideline and the present
study used current protocol prepared regarding rational
use of ceftriaxone.
Analysis using binary logistic regression and multivari-
ate logistic regression indicated that gender, age groups,
department types, units of admission and diagnosis types
not associated with inappropriate ceftriaxone usage in
the present study. This was different from the study
done at Thailand, in which female gender was associated
with appropriateness of ceftriaxone usage [28]. This dif-
ference may be due to the enrollment of more propor-
tion of females in the latter study (60.8 %) compared to
the present study (46.2 %). By contrast, multivariate lo-
gistic regression showed a significant positive association
between empiric treatment and inappropriate ceftriax-
one usage in the present study. This implies that empiric
treatment with ceftriaxone was significantly associated
with its inappropriate use.
Conclusion
This study revealed that both utilization rate and in-
appropriate use of ceftriaxone were very high in the
medical and emergency wards of Tikur Anbessa Special-
ized Hospital. This may lead to emergence of resistant
pathogens which in turn compromises its effectiveness
leading to treatment failure and increased cost of ther-
apy. The inappropriate utilization of ceftriaxone may
also compromise patient safety. Therefore, prescribers
should limit the use of ceftriaxone only for infections
that are proven or strongly suspected to be caused by
bacteria. For example, the empiric use of this drug for
cases other than its primary indications as in neutopenic
fever, lymphadenitis, etc should be avoided. Prescribers
should also direct therapy with C&S test result whenever
it is possible. Generally, adherence to current evidence-
based guidelines is recommended. The hospital (TASH)
should also realize continuous and ongoing drug use
evaluation; improve the suitability of antibiotics use
through the intensification of educational programs, estab-
lish an antimicrobial stewardship program, strengthen the
DTC unit and capacitate clinical pharmacists in monitoring
issues related to drug therapy.
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Limitations of the study
The present study focused only on internal medicine
and emergency departments. But, a more representative
result would be obtained if other departments (for ex-
ample, surgical and orthopedic) were included. Add-
itionally, local prospective studies done on drug
utilization of ceftriaxone are limited. Hence, it was not
possible to make comparison as the reader wanted to
see. The study did not also show the period prevalence
of ceftriaxone utilization rather it showed the point
prevalence alone.
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